Connection

Barbara Tilley to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Barbara Tilley has written about Parkinson Disease.
Barbara Tilley
Connection Strength
5.259
Parkinson Disease
  1. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.364
  2. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.343
  3. Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Stat Methods Med Res. 2016 04; 25(2):821-37.
    View in: PubMed
    Score: 0.339
  4. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.331
  5. Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1453-60.
    View in: PubMed
    Score: 0.268
  6. Minority enrollment in Parkinson's disease clinical trials. Parkinsonism Relat Disord. 2009 May; 15(4):258-62.
    View in: PubMed
    Score: 0.251
  7. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke. 2007 Feb; 38(2 Suppl):800-3.
    View in: PubMed
    Score: 0.226
  8. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
    View in: PubMed
    Score: 0.212
  9. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.195
  10. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
    View in: PubMed
    Score: 0.167
  11. Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action. Mov Disord. 2022 10; 37(10):1990-1995.
    View in: PubMed
    Score: 0.165
  12. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.118
  13. Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 07; 205:93-98.
    View in: PubMed
    Score: 0.114
  14. Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci. 2017 Apr 15; 375:355-359.
    View in: PubMed
    Score: 0.113
  15. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
    View in: PubMed
    Score: 0.112
  16. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.111
  17. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9.
    View in: PubMed
    Score: 0.102
  18. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
    View in: PubMed
    Score: 0.098
  19. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.098
  20. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.095
  21. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun; 71(6):710-6.
    View in: PubMed
    Score: 0.094
  22. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014 Mar; 21(3):519-24.
    View in: PubMed
    Score: 0.091
  23. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.088
  24. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015 Jan; 22(1):37-43.
    View in: PubMed
    Score: 0.087
  25. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.083
  26. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.082
  27. Fall frequency and risk assessment in early Parkinson's disease. Parkinsonism Relat Disord. 2012 Aug; 18(7):837-41.
    View in: PubMed
    Score: 0.081
  28. A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials. 2012 Apr; 9(2):188-97.
    View in: PubMed
    Score: 0.081
  29. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.078
  30. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.074
  31. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010 Jun 15; 25(8):1082-6.
    View in: PubMed
    Score: 0.071
  32. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.068
  33. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep; 66(9):1099-104.
    View in: PubMed
    Score: 0.067
  34. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.064
  35. Factors influencing physician referrals of patients to clinical trials. J Natl Med Assoc. 2008 Nov; 100(11):1298-303.
    View in: PubMed
    Score: 0.064
  36. Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 2008 Jul-Aug; 31(4):189-96.
    View in: PubMed
    Score: 0.062
  37. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
    View in: PubMed
    Score: 0.057
  38. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.056
  39. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.049
  40. Communicating with participants during the conduct of multi-center clinical trials. Clin Trials. 2016 12; 13(6):592-596.
    View in: PubMed
    Score: 0.027
  41. Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics. 2005 Jun; 61(2):532-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.